Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Investigational Site Number 1580003, Taichung

Investigational Site Number 1580005, Tainan Hsien

Investigational Site Number 1580004, Taipei

Investigational Site Number 4100010, Guri-Si, Gyeonggi-Do

Investigational Site Number 4100003, Seongnam-si

Investigational Site Number 4100009, Ansan-si

Investigational Site Number 4580001, Kelantan

Investigational Site Number 4100005, Wŏnju

Investigational Site Number 4100012, Busan

Investigational Site Number 4580005, Kuala Lumpur

Investigational Site Number 4580003, Kuala Lumpur

Investigational Site Number 4100004, Gwangju

Investigational Site Number 4580004, Seremban

Investigational Site Number 4580006, Kuching

Investigational Site Number 1560006, Beijing

Investigational Site Number 1560049, Beijing

Investigational Site Number 1560003, Shenyang

Investigational Site Number 1560031, Jinzhou

Investigational Site Number 1560009, Changchun

Investigational Site Number 1560027, Changchun

Investigational Site Number 1560040, Yanji

Investigational Site Number 1560035, Harbin

Investigational Site Number 1560036, Harbin

Investigational Site Number 1560013, Shanghai

Investigational Site Number 1560007, Shanghai

Investigational Site Number 1560004, Shanghai

Investigational Site Number 1560022, Nanjing

Investigational Site Number 1560002, Zhenjiang

Investigational Site Number 1560019, Suzhou

Investigational Site Number 1560005, Jinan

Investigational Site Number 1560032, Qingdao

Investigational Site Number 1560021, Tianjin

Investigational Site Number 1560017, Tianjin

Investigational Site Number 1560052, Jinhua

Investigational Site Number 1560037, Chongqing

Investigational Site Number 1560050, Chongqing

Investigational Site Number 1560016, Changsha

Investigational Site Number 1560015, Zhuzhou

Investigational Site Number 1560060, Yueyang

Investigational Site Number 1560018, Wuhan

Investigational Site Number 1560033, Guangzhou

Investigational Site Number 1560048, Huizhou

Investigational Site Number 1560054, Shenzhen

Investigational Site Number 1560041, Nanning

Investigational Site Number 1560053, Chengdu

Investigational Site Number 1560056, Chengdu

Investigational Site Number 1560057, Zigong

Investigational Site Number 1560008, Xi'an

Investigational Site Number 1560030, Xining

Investigational Site Number 1560058, Ürümqi

Investigational Site Number 1560001, Beijing

Investigational Site Number 1560039, Cangzhou

Investigational Site Number 1560010, Chenzhou

Investigational Site Number 1560044, Dongguan

Investigational Site Number 1560028, Guangzhou

Investigational Site Number 1560023, Hangzhou

Investigational Site Number 3440001, Hong Kong

Investigational Site Number 1560026, Huanggang

Investigational Site Number 1560025, Huangshi

Investigational Site Number 1560034, Huzhou

Investigational Site Number 1560014, Nanjing

Investigational Site Number 1560043, Nanjing

Investigational Site Number 1560038, Qinhuangdao

Investigational Site Number 1560029, Shanghai

Investigational Site Number 1560059, Suzhou

Investigational Site Number 1560055, Xi'an

Investigational Site Number 1560046, Yueyang

Investigational Site Number 1560045, Zhengzhou

Investigational Site Number 4580002, Putrajaya

Investigational Site Number 1560012, Handan

Investigational Site Number 1560011, Hengshui

Investigational Site Number 1560024, Hohhot

Investigational Site Number 1560047, Hohhot

Investigational Site Number 1560051, Xingtai

Investigational Site Number 4100016, Seoul

Investigational Site Number 4100011, Seoul

Investigational Site Number 4100013, Seoul

Investigational Site Number 4100001, Seoul

Investigational Site Number 4100002, Seoul